NICE uncertain about cost and long-term benefit of Roche's melanoma drug
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has not recommended Roche's Zelboraf (vemurafenib), for the treatment of unresectable locally advanced or metastatic BRAF V600 mutation-positive melanoma in its daft guidance. The institute said it was uncertain about both the long-term effect of drug on survival and its cost, even though Roche had put forward a patient access scheme.